Though milia tends to go away on their own, the best treatments and prevention methods include retinoids and exfoliants. Shop ...

The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 ...

Q4 2024 Earnings Conference Call February 7, 2025 3:00 AM ETCompany ParticipantsNicolas Hieronimus - CEOChristophe Babule ...

We explore the history of global pharmaceutical group Hoffmann-La Roche ... in 1915, Roche found itself facing an international and financial crisis. The German’s boycotted its products and ...

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and sa ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

New 5mg tablet offers the same established efficacy and safety as the Evrysdi oral solution for individuals living with spinal muscular atrophy.

1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

has app Roche achieved a sales growth of 7% (3% in CHF) in 2024, citing strong demand for pharmaceutical products. As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone ...